Moreover, we identified a novel mechanism that colchicine slowed AAA development by inactivating the WNT/β-catenin pathway in a methyltransferase-like 14 (METTL14)/YTH domain containing-1 (YTHDC1)/sclerostin (SOST)-dependent manner to maintain vascular SMC homeostasis and prevent vascular inflammation. Here, SOST is linked to triple-A syndrome.